MilliporeSigma adds first non-mammalian cell line to portfolio

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Cast08)
(Image: Getty/Cast08)

Related tags: Cell line, Cell line development, Vaccine, Gene therapy, Virus

MilliporeSigma collaborates with GlycoBac to provide an Sf-9 insect cell line for vaccine and gene therapy development.

GlycoBac, a biotechnology company that spun-out of the University of Wyoming, will provide its rhabdovirus-negative (RVN) cell line to allow MilliporeSigma, a contract development and manufacturing organization (CDMO) to offer the first Sf-9 platform in combination with a rhabdovirus-free insect cell line to provide a streamlined insect cell line production. The cell line will also have a corresponding chemically defined cell culture medium.

Nikolai Stankiewicz, global product manager of cell culture media and biopharma materials at MilliporeSigma, told us that this Sf-rhabdovirus-negative cell line will accelerate the biomanufacturing processes by eliminating the time needed to remove the rhabdovirus, which is necessary for traditional processes. Rhabdovirus is a process contaminant that clients often have to remove for the safety of the cell line.

This platform will be the first non-mammalian cell line in MilliporeSigma’s cell culture portfolio. With this addition, the company’s clients will have access to a vehicle for recombinant protein expression, virus-like particle vaccines and adeno-associated virus (AAV)-based gene therapy production.

According to Stankiewicz, the Sf-RVN cell line and an additional ex-cell CD-insect medium platform prototype are currently being evaluated by partners focusing on AAV production to meet the demands of commercial-scale production. The new platform is capable of producing all therapeutic classes that are traditionally manufactured with insect cells.

Related news

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us


View more